comparemela.com

Latest Breaking News On - Sandoz - Page 7 : comparemela.com

Trastuzumab Biosimilar Receives CHMP Recommendation for HER2+ Breast and Gastric Cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization of EirGenix’s biosimilar for trastuzumab for the treatment of patients with HER2-positive breast and metastatic gastric cancers.

Sandoz Receives FDA Approval For Tyruko® (Natalizumab-Sztn), The First And Only FDA-Approved Biosimilar For Relapsing Forms Of Multiple Sclerosis - Life Sciences, Biotechnology & Nanotechnology

On August 25, 2023, Sandoz announced that the FDA has approved its biosimilar Tyruko® (natalizumab-sztn), developed by Polpharma Biologics. Tyruko® injection is the first and only FDA-approved.

Novartis Sandoz targets biosimilar version of J&J drug in Samsung deal

FRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug Stelara under a collaboration deal with Samsung Bioepis. For Sandoz, which is due to become an independent company early next month, the transaction means more investment in the growing market of biosimilars, which are lower-cost copies of complex biotech drugs that have lost patent protection.

Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK

The reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders including Crohn s disease, plaque psoriasis,.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.